---
title: "ADC Therapeutics Q2 earnings preview"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295700574.md"
description: "ADC Therapeutics (ADCT) is set to report Q2 earnings on August 13th before market open. Consensus estimates project an EPS of -$0.22, a 12% year-over-year improvement, and revenue of $18.9 million, up 0.3% annually. Historically, the company has missed EPS estimates 100% of the time over the last two years but met revenue expectations 50% of the time."
datetime: "2026-08-12T19:30:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295700574.md)
  - [en](https://longbridge.com/en/news/295700574.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295700574.md)
generator: "portal-rs"
---

# ADC Therapeutics Q2 earnings preview

ADC Therapeutics (ADCT) is scheduled to announce Q2 earnings results on Thursday, August 13th, before market open. The consensus EPS Estimate is -$0.22 (+12.0% Y/Y) and the consensus Revenue Estimate is $18.9M (+0.3% Y/Y). Over the last 2 years, ADCT has beaten EPS estimates 0% of the time and has beaten revenue estimates 50% of the time. More on A...

### Related Stocks

- [ADCT.US](https://longbridge.com/en/quote/ADCT.US.md)

## Related News & Research

- [ADCT: Q2 2026 delivered stable sales, improved losses, and regulatory challenges for ZYNLONTA](https://longbridge.com/en/news/295792223.md)
- [ADC Therapeutics Q2 loss narrows; cuts 17% workforce](https://longbridge.com/en/news/295791965.md)
- [ADC Therapeutics posts corporate presentation highlighting Zynlonta growth opportunity in B-cell lymphomas](https://longbridge.com/en/news/295800995.md)
- [ADC Therapeutics Q2 2026 Earnings: Lower Spending Narrows the Loss](https://longbridge.com/en/news/295792525.md)
- [Bank of America Securities Keeps Their Buy Rating on Agree Realty (ADC)](https://longbridge.com/en/news/296102817.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**